As our results show an essential role for GSK-3β-mediated T-bet signaling in the T/I-induced activation of CD4+ lymphocytes, further research of the identified signaling pathway will lead to a strategy for preventing abnormal T lymphocyte activation and may lead to treatments for diseases such as GVHD. Here, GSK3B is linked to graft versus host disease.